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Objective—Proteinase-activated receptor-2 is widely expressed in vascular tissue and in highly vascularized organs in
humans and other species. Its activation mainly causes endothelium-dependent vasorelaxation in vitro and hypotension
in vivo. Here, using nonobese diabetic (NOD) mice at different disease stages, we have evaluated the role of PAR2 in
the arterial vascular response during diabetes progression.
Methods and Results—High (NOD-II; 20 to 500 mg/dL) or severe glycosuria (NOD-III; 500 to 1000 mg/dL) provokes a
progressive reduction in the response to acetylcholine paralleled by an increase in the vasodilatory response to PAR2
stimulation. Western blot and quantitative real-time polymerase chain reaction (RT-PCR) studies showed that this effect
is tied to an increased expression of PAR2 coupled to cyclooxygenase-2 expression. Pharmacological dissection
performed with specific inhibitors confirmed the functional involvement of cyclooxygenase-2 in PAR2 vasodilatory
effect. This vasodilatory response was confirmed to be dependent on expression of PAR2 in the smooth muscle
component by immunohistochemistry studies performed on aorta isolated by both NOD-III and transgenic PAR2 mice.
Conclusions—Our data demonstrate an important role for PAR2 in modulating vascular arterial response in diabetes and
suggest that this receptor could represent an useful therapeutic target. (Arterioscler Thromb Vasc Biol. 2005;25:2349-2354.)
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Proteinase-activated receptors (PARs) are a recently de-scribed novel family of 7-transmembrane G-protein-
coupled receptors.1–3 PARs are activated enzymatically
through proteolysis of the receptor by a well-characterized
family of enzymes that require serine within active site, the
serine proteases. On cleavage at these specific sites, the new
N-terminal for each receptor functions as a tethered ligand.2
At the present stage, 4 subtypes PARs have been character-
ized: PAR1,4 PAR3,5 and PAR4,6 selectively activated by
thrombin and PAR2 that is activated by trypsin, tryptase,
tissue factor, factor VII, and factor X.1
PAR2 has been shown to be involved in cardiovascular
function.7,8 Functional studies have shown that activation of
the receptor by using a small agonist peptide derived from the
tethered ligand sequence (PAR2AP) causes an endothelium-
dependent vasodilatation.9–13 Subsequent studies have clearly
shown that PAR2 is expressed in the human endothelial14 and
smooth muscle cells.15 Systemic administration of PAR2AP
in vivo in rats and mice causes hypotension.10,11,16,17 Interest-
ingly, also in humans in vivo PAR2 AP causes vasodilatation
that is dependent on nitric oxide (NO) release and prosta-
noids.18 As opposed to PAR1, PAR2 expression is upregulated
by inflammatory stimuli such as tumor necrosis factor-,
bacterial endotoxin (lipopolysaccharide [LPS]) and IL-1 in
endothelial cells.16,19,20 Likewise, LPS administration to rats
increases PAR2 expression on endothelium and smooth mus-
cle cells from both jugular vein and carotid artery, which
translates in an increased vasodilatory response to PAR2
AP.16 Consistent with these findings, the dose necessary to
activate the receptor in several inflammatory conditions is
reduced to 1 or 2 orders of magnitude in comparison to
normal conditions. Whereas all these data suggest a role for
PAR2 in cardiovascular inflammation, it is unclear whether
the activation of this receptor plays a pathological or com-
pensatory role.20,21
One example of endothelial dysfunction coupled to cardio-
vascular inflammation is represented by diabetes. Duration of
diabetes and poor glycemic control are the main predictor
factors for peripheral arterial disease, indicating a close link
between metabolic impairment and arterial injury.22,23 Al-
though peripheral arterial disease results from atherosclerotic
narrowing of the blood vessel lumen, endothelial dysfunction
has been shown to play a role in the progression of this
disease. Further, these processes are enhanced by the meta-
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bolic disturbances associated with diabetes and denervation
of the smooth muscle of the tunica media of arteries caused
by the diabetic neuropathy. Whether PAR2 plays a role in the
pathogenesis of arterial dysfunction in diabetes and if it is
upregulated in this condition are unknown.
In the present study, by using a genetic mouse model of
type I diabetes and PAR2 transgenic mice, we have investi-
gated the role of PAR2 in vessel function during the disease
progression. The results of our studies indicate that arterial
expression of PAR2 increases in response to diseases progres-
sion and exerts a potent vasorelaxant effect, suggesting that
development of PAR2 agonist might be helpful in treating
patients with diabetic arthropathy.
Materials and Methods
Animals
Female nonobese diabetic mice (NOD/Ltj) and CD-1 mice were
purchased from Charles River (Italy). CD-1 mice were used as
control animal because they display a similar pattern of contraction
and relaxation to NOD-I (Figure I, available online at http://
atvb.ahajournals.org). Transgenic PAR2 (tg-PAR2) mice were bred at
University of Siena and have been previously described.24 NOD
mice were divided according to the glycosuria value (Figure II,
available online at http://atvb.ahajournals.org) in the following
groups: NOD- I: low or null glycosuria (52 weeks; 0 to 20 mg/dL);
NOD-II: high glycosuria (133; 20 to 500 mg/dL); and NOD-III
severe glycosuria (223; 500 to 1000 mg/dL). For further details,
see http://atvb.ahajournals.org.
In Vitro Experimental Protocols
In each experiment, rings were standardized using phenylephrine
(1 mol/L) until the responses were reproducible. To evaluate tissue
vasorelaxation, cumulative concentration response curve to Ach (10
nmol to 30 mol/L), and to the PAR2 tethered ligand peptide (10
nmol to 30 mol/L) were performed on 5HT (3107 mol) precon-
tracted rings. Curves to PAR2AP were constructed in the absence and
presence of L-NAME (100 mol/L, 20 minutes), 1400 W (10 mol/L),
ibuprofen (10 mol/L), DFP (10 mol/L), FR-122047 (20 mol/L),
and SQ-22,536 (100 mol/L). When L-NAME was added, a sub-
maximal dose (EC80) of 5-HT (3108 mol) was used.
Western Blotting
Western blotting studies were performed on aortic tissue samples
homogenized in lysis buffer using a Talon homogenizer and were
processed identically. The immunoblots were developed with 1:500
dilutions for PAR2 and 1:1000 for COX-2 and the signal was
detected with the ECL System according to the manufacturer’s
instructions (Amersham Pharmacia Biotech).
Quantitative Real-Time Polymerase Chain
Reaction Studies
After the mice had been killed, aortas were removed and immedi-
ately snap-frozen on liquid nitrogen (LN2) and stored at 80°C until
used. Total RNA was isolated using TRIzol reagent (Life Technol-
ogies, Milan, Italy) as previously described.26,27 Quantification of the
expression mouse genes was performed by quantitative real-time
polymerase chain reaction (RT-PCR) by using specific primers.
Immunohistochemistry
The aortas from the different groups of mice were fixed with
buffered formalin (5%) for 24 hours. Tissue sections (6 m) were
stained for PAR2 receptors by an immunoperoxidase method. The
primary polyclonal antibody (Ab) used was a goat polyclonal Ab
raised against the carboxyl terminus of PAR2 of human origin, and
the specificity of the antibody was tested using the blocking peptide
(sc-8205P). The Ab was used at dilution of 1:200.
Statistical Analysis
Data are expressed as meanSEM. The level of statistical signifi-
cance was determined by 1-way analysis of variance (ANOVA)
followed by Bonferroni’s t-test for multiple comparisons, using the
GraphPad Prism software.
Results
Diabetes Progression Increases PAR-2AP–Induced
Vasodilatation and Upregulates PAR-2 and
COX-2 Expression
In NODI and CD1 mice, that have normal glycosuria, the
relaxant response induced by PAR2AP on isolated aorta is
similar (Figure 1a). The disease progression leads to a
significant decrease in the relaxant response to acetylcholine
(Figure 1d) with a concomitant increase in PAR2AP-induced
vasodilatation of NOD-II (Figure 1b) and NOD-III (Figure
1c) aortas. There is a significant shift of PAR2AP-induced
vasorelaxant effect of the EC50 from 1106 mol of NOD-I
aorta to 6.5107 for NOD-II aorta and to 4107 mol/L for
NOD-III aorta. The scramble peptide LSIGRL-NH2 was
inactive on both NOD-I and NOD-III mice aorta (Figure III,
available online at http://atvb.ahajournals.org). Because it is
known that inflammatory stimuli can upregulate both PAR2
and COX-2 expression, we have evaluated expression of
PAR2 in aortas obtained from normal and NOD mice at
different stages of illness (NOD-I, NOD-II, and NOD-III).
Quantitative RT-PCR showed an increase in mRNA expres-
sion of PAR2 (Figure 2A, panel f) and COX-2 (Figure 2A,
Figure 1. The vasorelaxant effect produced by PAR2AP on
NOD-I aorta (panel a; n8) is not significantly different from that
produced on CD-1 (52 weeks) aorta (n8, a). The vasorelax-
ant effect is significantly potentiated in NOD-II aorta versus
CD-1 (133 weeks) (n8, b) and in NOD-III vs CD-1 (223
weeks) aorta (n6, c). The disease progression causes a clear
reduction in the acetylcholine-induced relaxation of NOD mouse
isolated aortas (d); ***P0.001; **P0.01; n represents the num-
ber of mice used from each animal were prepared at least 4
aorta rings.
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panel b), whereas PAR1 (Figure 2A panel e), COX-1 (Figure
2A, panel a), inducible nitric oxide synthase (iNOS) (Figure
2A, panel d), and endothelial nitric oxide synthase (eNOS)
(Figure 2A, panel c) mRNA levels were unchanged. Western
blot analysis showed that there is a concomitant significant
increase of PAR2 and COX-2 protein expression in NOD-II
and NOD-III aortas when compared with either NOD-I or
CD-1 aortas (Figure 2B), whereas iNOS was unchanged (data
not shown).
Role of NO and Prostanoids in PAR2AP-Induced
Vasodilatation in NOD Mice
Next, to investigate on the role played by NO and prosta-
noids, we tested the effect of l-NAME and ibuprofen. Each
drug was used at concentrations known to inhibit NO-
dependent vasorelaxation and COX-1/COX-2 activity, re-
spectively. Incubation of aorta rings of CD-1 (Figure 3a) or
NODI (Figure 3b) with L-NAME abrogated the vasodilatory
effect of PAR2AP. Conversely, ibuprofen did not affect
PAR2AP-induced vasodilatation of either CD-1(Figure 3a) or
NODI (Figure 3b) mouse aorta.
Aorta isolated from NOD-II mice show a reduced inhibi-
tory effect of L-NAME that was removed at lower doses with
a significant shift of Emax (maximal relaxation achievable)
from 90% to 25% (Figure 3d). Similarly, there is a significant
inhibition by ibuprofen (Figure 3d) particularly marked at
lower doses of PAR2AP. NOD-III isolated aortas displayed a
similar inhibitory pattern with a more marked inhibitory
effect displayed by ibuprofen (Figure 3e). When aortic rings
were incubated with both ibuprofen and L-NAME, there was
a further significant inhibition of the relaxant response to
PAR2AP. Prostaglandins produce their effect through cAMP.
To further confirm cAMP involvement we used SQ-22,536
an inhibitor of adenylate cyclase. SQ-22,536 significantly
reduced PAR2AP-induced vasorelaxation of NOD-III aorta
(Figure 3f), but it was ineffective in NOD-I aortas (Figure
3c). Functional studies performed on aortas isolated by CD-1
(Figure 4a), NOD-I (Figure 4b), and NOD-III (Figure 4c) by
Figure 2. A, RT-PCR analysis shows that there is a
significant increase in mRNA for PAR2 (f), COX-2
(b) but not PAR1 (e), eNOS (c), COX-1 (a), and
iNOS (d) in aortas isolated from NOD-II and NOD-
III mice *P0.05 vs their relative control. B, West-
ern blot analysis shows PAR2 and COX-2 protein
expression. Analysis was performed on aortas from
NOD-II, NOD-III, and tg-PAR-2 (Tg) mice. Experi-
ments were performed in triplicate (n3 mice).
Figure 3. L-NAME (100 mol/L) but not
ibuprofen (10 mol/L) significantly inhib-
its PAR2AP-relaxation of aortas isolated
by either CD1 (panel a; n6) or NOD-I
(panel b; n6) mice. Both NOD-II (panel
d; n6) and NOD-III (panel e; n4)
mouse aortas displayed a significant
reduction in the L-NAME inhibitory effect
and the appearance of a significant in-
hibitory effect of ibuprofen. Incubation
with L-NAME and ibuprofen further inhib-
ited the vasorelaxant response (panel e).
SQ-22,536 (100 mol/L), an inhibitor of
adenylate cyclase did not modify the
PAR2AP induced vasorelaxant response
in NOD-I mice (panel c; n6) but
strongly inhibited PAR2AP-induced relax-
ation in NOD-III mouse aorta (panel f;
n5). Data are expressed as
meanSEM. **P0.01, ***P0.001 vs
vehicle; n represents the number of mice
used, from each animal were prepared at
least 4 aorta rings.
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using specific inhibitors of COX-1 (FR-122047), COX-2
(DFP), and iNOS (1400W) showed that the major contribute
to the relaxation observed in NOD-III mice is given by
prostanoids mainly derived by COX-2. These data fit well
with the increased COX-2 expression observed in NOD-II
and NOD-III mouse aortas (Figure 2). Aorta harvested form
CD-1 mice age-matched with NOD mice did not show any
change in relaxation induced by acetylcholine or PAR2AP;
similarly, glycosuria was unchanged (Figure I).
Tg-PAR2 Mice
To confirm these data, we used transgenic mice overexpress-
ing PAR2. The vasorelaxant response of NOD-III aorta to
PAR2AP (Figure 4a) is similar to that of tg-PAR2 mouse
isolated aorta (Figure 4c). Furthermore, similarly to what
happens in NOD-III aortas (Figure 4a), PAR2AP-induced
vasorelaxation is still present in endothelium-denuded aortic
rings obtained by tg-PAR2 mice (Figure 4c). These data
clearly suggest an active role of smooth muscle cells in
PAR2-mediated vasorelaxation in tg-PAR2 mice, suggesting
that a similar increase in PAR2 expression in the smooth
muscle component of NOD-II and NOD-III mice. We there-
fore evaluated the expression of PAR2 in situ by using
immunohistochemical staining of aortas obtained from wild-
type and NOD-III mice, as well as from transgenic overex-
pressing PAR2 (Figure 5). As shown in Figure 5, PAR2
expression was minimal but nonetheless detectable in a
patchy distribution in aorta and peri-aortal tissue of wild-type
mice with very low positive reaction on the smooth cell
component (Figure 5, panel A). By contrast, expression of
PAR2 was diffusely greater in tissues of NOD mice (Figure 5,
panel B). The specific staining for PAR2 we observed on the
smooth muscle cell component in aortas from NOD-III mice
(Figure 5, panel B) equaled, or exceeded, in strength that of
aortas from mice overexpressing PAR2 (Figure 5, panel C).
The positive staining was removed by addition of the block-
ing peptide confirming the specificity of the primary antibody
(Figure 5, panel D). Thus, the immunohistochemistry data
support the functional data. Next, to further address this
similarity between NOD-III and tg-PAR2 mice, we performed
a comparative study using ibuprofen, L-NAME, SQ-22,536,
DFP, and FR-122047. Similar to what happens in NOD-III
mice, ibuprofen (Figure 4e) and SQ-22,536 (Figure 4d) both
inhibited PAR2AP-induced vasorelaxation in intact rings
harvested from tg-PAR2 mice. As in NOD-III mice, L-NAME
inhibitory effect on tg-PAR2 mouse aorta was reduced as
Emax (Figure 4d). DFP, the selective COX-2, inhibitor
significantly reduced PAR-2AP–induced relaxation in NOD-
III aorta (Figure 4b). Conversely, the selective COX-1 inhib-
itor (FR-122047) that was ineffective in NOD-III mice
significantly inhibited PAR2AP-induced vasorelaxation in
tg-PAR2 mice whether DFP had no effect (Figure 4f).
Discussion
Cardiovascular diseases are currently the principal causes of
morbidity and mortality in patients with type I diabetes.22,23
The loss of modulator tone by the endothelium is considered
one of the critical factor in the development of diabetic
vascular diseases. There is evidence that an impaired re-
sponse to endothelium-dependent agonists in different vascu-
lar beds develops in response to both chemically induced and
Figure 4. Endothelium mechanical removal from
NOD-III (n5; a) and tg-PAR2 (n4; c) mouse aorta
does not abrogate PAR2AP relaxation. PAR2AP-
induced relaxation of NOD-III mouse aorta is sig-
nificantly inhibited by DFP only (n3; b). PAR2AP-
induced relaxation of tg-PAR2 mouse aorta is
significantly inhibited by ibuprofen (n4; e),
FR-122047 (n4; f) and SQ-22,536 (n4;d) and to
a lesser extent by L-NAME (n4; d), whereas DFP
(n3; f) has no effect. Data are expressed as
meanSEM. ***P0.001, ** P0.01; n represents
the number of mice used from each animal were
prepared at least 4 aorta rings.
Figure 5. Immunohistochemical staining for PAR2 in aortas from
wild-type mouse (A), NOD III (B), and a tg-PAR2 mice (C). The
positive staining was removed by addition of the blocking pep-
tide confirming the specificity of the primary antibody (D). Origi-
nal magnification (100) shows a clear intense staining for the
smooth muscle component and of the peri-aortal area.
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genetic models of type I diabetes or in vivo in experimental
animals.28 A constant feature of these studies is an impaired
response to acetylcholine. We have recently shown that NOD
mice vessel reactivity follows the diabetes progression and, in
particular, there is an impairment of the vasorelaxant effect to
acetylcholine and isoprenaline.25,29
Here, we show that response to PAR2 selective stimulation
is increased in diabetic mice with a clear shift of the EC50.
This increased response is strictly linked to the disease
progression being maximal in NOD-III mice in which vaso-
dilatation to acetylcholine is strongly impaired through an
alteration of the post-translational mechanisms involved in
eNOS regulation.25 The vasorelaxant effect of PAR2 on
vessels is linked to the presence of an intact endothelium and
only in part through the NO release as demonstrated both in
vitro and in vivo.7,10,11,30 Recently it has been shown that
PAR2 activation increases COX-2 protein and mRNA expres-
sion and promotes PGI2 release from human umbilical vein
endothelial cell. Thus, COX-2 induction takes part in the
functional response of endothelial cells to PAR2 activation,31
suggesting that PAR2 promotes a sustained upregulation of
prostanoid production in endothelium. To gain further in-
sights into this mechanism we have analyzed the effect of
L-NAME, an NO synthase inhibitor, and ibuprofen, a COX-
1/2 inhibitor. In control and NOD-I mice (low or null
glycosuria), L-NAME virtually abrogates the PAR2AP in-
duced vasorelaxation whereas ibuprofen was ineffective.
Conversely, when diabetes is clearly established, such as in
NOD-II mice, there is a reduction in the inhibitory effect of
L-NAME and the appearance of ibuprofen inhibitory effect on
PAR2AP-induced relaxation, which is particularly evident at
the lower doses of PAR2AP. In NOD-III mice, that have a
more severe glycosuria, there is equally a loss in efficacy of
L-NAME and the inhibitory effect of ibuprofen is signifi-
cantly more pronounced. The simultaneous administration of
ibuprofen and L-NAME further inhibited the relaxant re-
sponse to PAR-2AP. These results imply that, as the disease
progresses, there is a gradual switch of the vessel relaxant
mechanism toward the PAR2 signaling pathway with an
increased contribute of the cyclooxygenase pathway. Func-
tional studies performed using selective inhibitors of COX-1
(FR-122047) and COX-2 (DFP) confirmed that PAR-2AP
induced vasorelaxation occurs with a COX-independent
mechanism in control condition, eg, in NOD-I and CD1
mouse aortas. Conversely, in pathological condition, such as
in NOD-III mice, there is a clear involvement of prostanoids,
mainly driven by COX-2 as suggested by the lack of
inhibitory effect of the selective COX-1 inhibitor FR-122047
and by the marked effect of SQ22,536, a selective cAMP
inhibitor. This interpretation is supported by the molecular
studies that clearly show by quantitative RT-PCR an increase
in PAR2 and COX-2 mRNAs expression that correlates well
with protein expression in NOD-III mice. Interestingly, the
immunohistochemistry study clearly demonstrated that dia-
betes development causes an increased expression of PAR2
on the smooth muscle cell component and in peri-aortic areas.
Thus, it appears that there is a linkage among NO, PAR2, and
COX-2 that becomes evident in pathological condition. A
similar linkage among PAR2AP vasodilatory effect, NO, and
COX products has been recently shown also in human
volunteers18 and in experimental animals.30 Using rat aorta
has been shown that basal NO modulates the vascular effects
linked to PAR2 activation and that both cGMP and cAMP are
involved.30 In human healthy volunteers it has been shown
that vasodilatation of the dorsal hand vein induced by local
administration of PAR2AP is inhibited by both L-NAME and
aspirin.16 In this context it is important to note that PAR2, as
opposed to PAR1, can be upregulated by inflammatory stimuli
such as tumor necrosis factor-, IL-1, and LPS.16 This
upregulation is also present in vivo after administration of
LPS in the arterial and venous tissue of rats19 and in vitro in
human coronary vessels.32 Similar results that further support
the hypothesis that PAR2 can be “unmasked” by an inflam-
matory cardiovascular event were obtained by using an
animal model of balloon vascular injury.33
Because in our vessel preparation there is still a residual
activity to Ach, and to better-understand the role of endothe-
lium in our experimental condition, we tested the effect of
PAR2AP in rings where the endothelium was mechanically
removed. Endothelium removal in NOD-I mice comported a
complete loss of the relaxing activity similar to what can be
observed in CD-1 mice as it has been demonstrated also by
others. Conversely, no significant changes were observed in
NOD-III mice in relaxation in aorta after endothelium re-
moval, furthermore the pattern of relaxation operated by
PAR-2AP in vitro was very close to that displayed by aorta
isolated by tg-PAR-2 mice. In a more complete analysis of
the response to PAR2AP of tg- PAR2 aorta, the similarity with
the response to NOD-III mice was even more striking.
Similar to NOD-III isolated aortas, tg-PAR2 mice isolated
aortas displayed a reduced vasodilatory response to PAR2AP
in presence of ibuprofen and SQ-22,546 as well as reduced
inhibition by L-NAME. Interestingly, the selective COX-1
inhibitor was ineffective on aortas isolated from NOD-III,
whereas it significantly inhibited tg-PAR2 mouse aorta, fur-
ther supporting that the disease development causes a selec-
tive induction of the COX-2 isoform. Thus, these data support
the hypothesis that after endothelial injury there is an in-
creased expression of PAR2 on the smooth muscle cells to
counterbalance the loss in vasodilatory component. In NOD-
III mice, the prostanoid effect is mainly driven by COX-2 as
opposed to tg-PAR-2 mice, in which it is mainly driven by
COX-1. This is not surprising because in NOD mice, the slow
development of diabetes can cause the COX-2 induction,
whereas in tg-PAR-2 mice the increased expression of PAR-2
is obtained by genetic manipulation and, for this reason,
couples to the constitutive form of the enzyme, ie, COX-1.
In conclusion, our data show that in diabetes development
there is a gradual switch of the vessel relaxant function
toward PAR2 and COX-2. This most likely represents a
functional response to the injury to the endothelium that in
this condition displays a reduced functionality. These data
also suggest that PAR2AP peptide may be useful vasodilator
in diabetes or in other pathology in which an endothelial
damage on inflammatory basis is present. In this context it
has been recently demonstrated a beneficial effect of PAR2AP
in a murine model of hind-limb ischemia in which PAR2AP
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administration increases capillarity resulting in an accelerated
hemodynamic recovery and enhanced limb rescue.34
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Materials and Methods 
Reagents 
L-phenylephrine (PE), acetylcholine (Ach), serotonin (5-HT), sodium nitroprusside (SNP), Nω-
nitro-L-arginine methyl ester (L-NAME), ibuprofen, SQ-22,536, Trypsin (16,400U/mg) were 
purchased from Sigma Chemical Co. (Milano-Italy). DFP (5,5-dimethyl-3-(-2propoxy)a-(4-
methanesulfonylphenyl)-2(5H)-furanone) was a generous gift of Prof. TD Warner (UK). 1400W 
and FR-122047 were purchased from Tocris Cookson (Bristol UK). All salts used for Krebs 
solution preparation were purchased from Carlo Erba Reagenti (Milan, Italy). PAR2 agonist peptide 
(SLIGRL-NH2) and the scrambled peptide (LSIGRL-NH2) were a generous gift of prof 
V.Santagada and G Caliendo (Napoli, Italy).   Anti-PAR2 IgG (sc-8205) and the blocking peptide 
(sc-8205P) were purchased from Santa Cruz Biothechnology Inc (Santa Cruz, California, USA). 
Anti-COX-2 and anti iNOS were purchased from Cayman-Chemical (USA). All salts used for 
western blot analysis were purchased from ICN Biochemical (Eschwege, Germany).  
 
Animals 
Female Non Obese Diabetic mice (NOD/Ltj) and CD-1 mice, were purchased from Charles River 
(Italy). CD-1 mice were used as control animal since they display a similar pattern of contraction 
and relaxation to NOD I (supplemental fig.1) NOD mice exhibit a susceptibility to spontaneous 
development of autoimmune (type I) insulin dependent diabetes mellitus (IDDM). Diabetes 
development in NOD mice is characterised by lymphocyte infiltration into the pancreatic islets 
which progressively induces pancreatic β cell necrosis. Progressive reduction in pancreatic insulin 
content starts at about 12-16 weeks of age. Transgenic PAR2 (PAR2tg) mice were bread at 
University of Siena and have been previously described24. Briefly, a 140 Kb human BAC clone 
(identification no. 23C20) containing the entire genomic sequence of human PAR2 was used. This 
BAC DNA (5ng/µl) was microinjected into the pronuclei of FVB/N eggs. FO pups were screened 
for incorporation of the transgene using the human-specific PAR2 primer and it was confirmed by 
Southern blotting.  
 
NOD mice 
To assess the diabetic condition of NOD animals, glycosuria was evaluated weekly to select the 
animals. This method was used since it is non invasive and it well correlates with an increase in 
blood glucose25. The content of glucose in the urine was measured by using Trinder reaction 
(Glucose Trinder 100, Sigma Chemical Co. Milano, Italy). Mice were divided according to the 
glycosuria value (mg/dl) in the following groups: NOD- I: low or null glycosuria ( 5±2 weeks; 0-20 
mg/dl) ; NOD-II:  high glycosuria (13±3; 20-500 mg/dl) ; NOD-III severe glycosuria (22±3; 500-
1000 mg/dl). The day of the sacrifice blood glucose levels were also measured. Animals were 
sacrificed according to the glycemia/glycosuria levels and aortas were dissected and used for 
western blotting analysis or for tissue bath experiments.   
 
Tissue preparation.  
NOD, tg-PAR2 or CD-1 mice were sacrificed and thoracic aorta was rapidly dissected and cleaned 
from fat and connective tissue. Rings of 1.5-2 mm length were cut and mounted on wire myographs 
(Kent Instruments, Japan) filled with gassed Krebs solution (95% O2+ 5% CO2) at 37°C. Changes 
in isometric tension were recorded with PowerLab data acquisition system (Ugo Basile, Italy). The 
composition of the Krebs solution was as follows (mol/l): NaCl 0.118, KCl 0.0047, MgCl2 0.0012, 
KH2PO4 0.0012, CaCl2 0.0025, NaHCO3 0.025 and glucose 0.010. Rings were initially stretched 
until a resting tension of 1.5 g was reached and allowed to equilibrate for at least 40 minutes during 
which tension was adjusted, when necessary, to 1.5 g and bathing solution was periodically 
changed. In a preliminary study a resting tension of 1.5 g was found to develop the optimal tension 
to stimulation with contracting agents.  
 
In vitro experimental protocols.  
In each experiment rings were firstly challenged with PE (1 µM) until the responses were 
reproducible. Conversely, to evaluate tissue vasorelaxation, cumulative concentration response 
curve to Ach (10 nM-30 µM), to trypsin (0.01-10U/ml) and to the PAR2 tethered ligand peptide (10 
nM-30 µM) were performed on  5HT (3x10-7M)- precontracted rings.  Percent of relaxation was 
calculated as follows: drug induced vasorelaxation (g) / 5-HT induced contraction (g) x100. In 
another set of experiments, rings were denuded of the endothelium and a PAR2AP cumulative 
concentration-response curve was performed. To investigate the involvement of NO, prostanoids 
and cAMP, dose response curves to PAR2AP were constructed in the absence and presence of either 
NG-nitro-L-arginine methyl ester (L-NAME, 100µM, 20 minutes) to inhibit NOS, 1400W (10 µM) 
to inhibit iNOS, cyclooxygenase inhibitor ibuprofen (10 µM) to inhibit prostaglandin synthesis, 
DFP (10 µM) to inhibit COX-2, FR-122047 (20 µM) to inhibit COX-1, and SQ-22,536 (100 µM)  
to inhibit adenilate cyclase. When L-NAME was added, a submaximal dose (EC80) of 5-HT (3x10-
8M) was used. When rings were incubated with  L-NAME was reached an increase in tension in 
dyne/mg/wet tissue that did not significantly differ from that obtained using 5-HT at 3 x10-7 M 
alone (data non shown). The relaxation achieved at the higher dose tested is defined as Emax. 
 
Western Blotting.  
Aortic tissue samples were homogenised in lysis buffer (β-glycerophosphate 0.5 M, sodium 
orthovanadate 10mM, MgCl2 20mM, EGTA 10mM, DTT 100mM and protease inhibitors) using a 
Talon homogenizer, and were processed identically. Protein concentration was determined using 
Bradford assay (Bio-Rad Laboratories, Segrate, MI). Proteins (30 µg) were subjected to 
electrophoresis on an SDS 10% polyacrylamide gel and electrophoretically transferred onto a 
nitrocellulose transfer membrane (Protran, Schleicher & Schuell, Germany). The immunoblots were 
developed with 1:500 dilutions  for PAR2 and 1:1000 for COX-2 and the signal was detected with 
the ECL System according to the manufacturer’s instructions (Amersham Pharmacia Biotech).   
 Quantitative RT-PCR 
 After the mice had been killed, aortas were removed and  immediately snap-frozen on liquid 
nitrogen and stored at –80°C until used. Total RNA was isolated using TRIzol reagent (Life 
Technologies, Milan, Italy) as previously described26,27.  Quantification of the expression mouse 
genes was performed by  qRT-PCR. The sense and antisense primers for COX-1, COX-2, PAR1, 
PAR2, iNOS and eNOS were obtained from Stratagene (La Jolla, CA; ), Sigma Genosys (UK) or 
Maxim Biotech (San Francisco, CA).  All PCR primers were designed using software PRIMER3-
OUTPUT using published sequence data from the NCBI database. The RNA was reverse-
transcribed with Superscript III (Invitrogen) in 20 µl reaction volume using random primers. For 
RT-PCR, 100 ng template was used in a 25 µl containing 0.3 µM of each primer and 12.5 µl of 2 x 
SYBR Green PCR Master mix (Bio-Rad). All reactions were performed in triplicate and the thermal 
cycling conditions were as follows: 2 min at 95°C, followed by 50 cycles of 95°C for 10 sec, and 
60°C for 30 sec in an iCycler iQ instrument (Biorad, Hercules, CA). The mean value of the 
replicates for each sample was calculated and expressed as the cycle threshold (CT: cycle number at 
which each PCR reaction reaches a predetermined fluorescence threshold, set within the linear 
range of all reactions). The amount of gene expression was then calculated as the difference 
between the CT value of the sample for the target gene and the mean CT value of that sample for 
the endogenous control (GADPH).   
 
 
Immunohistochemistry.  
The aortas from the different groups of mice were fixed with buffered formalin (5%) for 24 hours. 
The samples were then dehydrated, cleared in toluene, and embedded in paraffin. Tissue sections (6 
µm) were stained for PAR2 receptors by an immunoperoxidase method. The sections were pre-
treated with 3% hydrogen peroxide to inhibit the activity of the endogenous peroxidase. For antigen 
retrieval, the sections were heated in a microwave for 20 min in citrate buffer 0.01M, pH 6.0,  and 
allowed to cool slowly to room temperature. All the sections were also incubated with 3% bovine 
serum albumin for 30 min at room temperature to block non-specific antibody binding. They were 
then incubated overnight at 4°C with the primary antibodies (Ab). The primary polyclonal Abs used 
was a goat  polyclonal Ab raised against the carboxyl terminus of PAR2 of human origin, and the 
specificity of the antibody was tested using the blocking peptide (sc-8205P) purchased from the 
same manufacturer (Santa Cruz Biotechnology, Inc., Santa Cruz, CA).  This Ab cross-reacts with 
mouse PAR2 and was used at dilution of 1:200. The sections were rinsed and incubated with sheep 
anti-goat IgG antibodies for 40 min at room temperature. The staining was revealed by adding 
peroxidase-antiperoxidase complex prepared from goat serum. Detection was accomplished by 
incubating in diamino-benzidine freshly dissolved in 0.03% H2O2 in 50 mM Tris-HCl pH 7.6. The 
sections were counterstained with haematoxylin. 
 
Statistical Analysis.   
Data are expressed as mean ± s.e. mean. The level of statistical significance was determined by one-
way analysis of variance (ANOVA) followed by Bonferroni’s t-test for multiple comparisons, using 
the GraphPad Prism software. 

 
